Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

AUGUST 10, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. About MyMD Pharmaceuticals, Inc.

Clinical Trials 105

Clinical Trials Pharmaceutical Research and Development CBD 105

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

The Cannigma

NOVEMBER 23, 2021

And for the most part, patients are undertaking this journey alone and often with little guidance. There is also a lack of access to healthcare professionals, and experts in the field, to guide patients through this complicated process. The Cannabis Enigma is a co-production of The Cannigma and Americans for Safe Access.

Data 52

Data Patients Access Wellness and Beauty 52

Cannabis Law Report

JANUARY 3, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Despite the recently announced national lockdown in the Netherlands, our CRO is continuing to screen and enroll patients,” stated Daniel Schneeberger, M.D., About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. Rex Merchant.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? ” Source BBC: [link]. PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Cannabis Law Report

JANUARY 6, 2022

An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. This blog post will explain how psilocybin patenting and other factors could make Oregon’s psilocybin program prohibitively expensive for low-income patients, and how big pharma is maneuvering to monopolize psychedelic therapy.

Access 52

Access Patients Research and Development Treatment 52

Cannabis Law Report

JUNE 7, 2021

The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinical trial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. Securities and Exchange Commission (“SEC”) on July 13, 2020.

Clinical Trials 105

Clinical Trials Patients THC Safety 105

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

The Cannigma

FEBRUARY 1, 2023

Patients are often left to their own devices when looking into cannabis and cancer, given the lack of clinical evidence, and stigma surrounding the use of the plant as medicine. Individuals who use cannabis-based medications often want to cure their cancer, not just reduce the symptoms that come with the condition. The answer: Maybe!

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

JULY 12, 2019

Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. “Our Work with U.S. Christy Curran.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

NORML

AUGUST 26, 2019

Virginia has been one of the most reluctant states to consider marijuana law reform, though it recently began allowing some forms of cannabis oil for approved patients. There are currently five “pharmaceutical processor” permit holders in Virginia, and they’re about to open for business.

Marijuana 208

Marijuana Legalization Programs Oil 208

Cannabis Law Report

JANUARY 28, 2022

By Maciej Konarowski, President of the Polish Medical Cannabis Patients Association and founder of the Can advocare law firm, and Conor O’Brien, Analyst at Prohibition Partners. Demand for medical cannabis from patients in Poland is growing fast, but the government is still failing to ensure adequate supply. 28 January 2022.

Legislation 52

Legislation Pharmaceutical Agriculture Cultivation 52

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

AUGUST 3, 2021

Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. Data Bridge sees strong psychedelics growth.

Research and Development 105

Research and Development Data Conditions Therapy 105

Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. billion, servicing nearly 340,000 active patients. In 2019, the island’s economy grew by 2.1% in real terms to £4.97 to reach 3.2

Programs 100

Programs Data Events Collective 100

Canna Law Blog

SEPTEMBER 6, 2023

This means that under both state and federal laws, only certain healthcare providers or licensed pharmacists can dispense (or even refill) Schedule III controlled substances. All of those clients have to deal with a myriad of healthcare law and regulatory issues under both federal and state law, and the cost of compliance is not cheap.

Research and Development 113

Research and Development DEA Marijuana Pharmaceutical 113

Cannabis Law Report

NOVEMBER 15, 2021

–(BUSINESS WIRE)– #earnings — Virpax ® Pharmaceuticals, Inc. Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. About Virpax Pharmaceuticals.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

AUGUST 29, 2021

ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/. The export to Brazil also confirms the regulatory pathway and acts as a proof of concept in the largest market in South America where we aim to establish long-lasting supply relationships with our Brazilian pharmaceutical partners.”.

Extraction 98

Extraction Supply Chain Research and Development CBD 98

NORML

SEPTEMBER 20, 2019

We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. And time was an issue, since her research projects involved suicidal combat veterans with PTSD and stage 4 cancer patients who didn’t have long to live. Dr. Sue Sisley.

DEA 227

DEA Research and Development Clinical Trials Patients 227

Cannabis Law Report

AUGUST 18, 2022

Among the first in the nation, Phillips Lytle’s Psychedelics Practice Team combines expertise in pharmaceutical science, FDA regulations and risk management to serve the legal needs of emerging bio-tech sectors. “It also creates new opportunities for researchers, entrepreneurs, investors and pharmaceutical companies.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

Veriheal

JUNE 19, 2023

The prominent players, as explained by the psychedelic market report, include Pfizer, Verrian, GlaxoSmithKline, COMPASS Pathways PLC, MindMed, Janssen Pharmaceuticals PLC, HAVN Life Sciences, Seelos Therapeutics, Field Trip Health, amongst others. Why Is the Psychedelics Market Growing? It was approved by the U.S.

Therapy 109

Therapy Treatment Patients Policy 109

Veriheal

DECEMBER 24, 2021

One of the original authors of the Compassionate Use of Medical Cannabis Pilot Program Act in 2013 (MCPP) — a law that led to the legalization of pharmaceutical-grade cannabis across the state of Illinois — says that growing demand and acceptance of the federally illegal plant has not reduced the risk of job loss.

Legislation 98

Legislation Recreational Patients Cannabis 98

The Cannigma

JUNE 14, 2021

For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. We are allowed to cultivate, manufacture, research, analyze and distribute cannabis for scientifical, medical and pharmaceutical research. Shutterstock).

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Cannabis Law Report

JULY 7, 2021

The country, which Tilray said has an estimated medical marijuana demand of more than 100,000 patients, legalized the drug for medical use in 2017 but has since relied on importing it. What they’re asking is … for information,” she said, like how the products are used, how patients can be instructed, and what dosage is. “We

Clinical Trials 105

Clinical Trials Education Data Pharmaceutical 105

Cannabis Law Report

APRIL 29, 2022

The product range is being manufactured to meet the growing demand for high quality medical cannabis products across Europe and builds on Curaleaf International being the first company to register a THC cannabis extract Active Pharmaceutical Ingredient (“API”) in Italy.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Patients 52

Cannabis Law Report

MARCH 22, 2020

A data firm is warning those infected with the novel coronoavirus to avoid consuming products that contain tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Data CEO Julie Armstrong said her company knows the COVID-19 affects the population in a similar way to influenza. World Health Organization (WHO).

THC 59

THC Clinical Trials Data Consumption 59

PrestoDoctor

SEPTEMBER 6, 2023

It has been a go-to option for healthcare professionals seeking to manage pain effectively for their patients. This has led many patients to explore cannabis as a potential substitute for prescription codeine. Additionally, common side effects such as drowsiness, constipation, and respiratory depression can be burdensome for patients.

Chronic Pain 105

Chronic Pain Research and Development Patients Cannabis 105

Cannabis Law Report

JANUARY 14, 2022

Is it a natural response to the fact that recreational is supposedly on the way or a the report suggests it’s hard as a patient to access so therefore people are just giving up. The current lack of market growth reflects an unfortunate reality in Germany that patient access to medical cannabis is still quite low.

Pharmaceutical 52

Pharmaceutical Extraction Oil Patients 52

Cannabis Law Report

JULY 29, 2021

ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/. To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

Extraction 98

Extraction Supply Chain THC Research and Development 98